Sonnet BioTherapeutics Holdings, Inc.

NasdaqCM SONN

Sonnet BioTherapeutics Holdings, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 49.43%

Sonnet BioTherapeutics Holdings, Inc. Gross Profit Margin is 49.43% for the Trailing 12 Months (TTM) ending September 30, 2024, a 1.39% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Sonnet BioTherapeutics Holdings, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was 48.75%, a 101.45% change year over year.
Sonnet BioTherapeutics Holdings, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -3,357.02%, a -91.78% change year over year.
Sonnet BioTherapeutics Holdings, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -1,750.46%.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqCM: SONN

Sonnet BioTherapeutics Holdings, Inc.

CEO	Dr. Pankaj Mohan Ph.D.
IPO Date	Oct. 31, 2006
Location	United States
Headquarters	100 Overlook Center
Employees	12
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.

Key trends

Past 5 years